Acadia: Don't expect Nuplazid NDA until 1Q 2015
This article was originally published in Scrip
Executive Summary
Not only did Acadia Pharmaceuticals disappoint investors by missing the mark in reporting the firm's quarterly earnings, but the company disclosed its new drug application (NDA) for its investigational Parkinson's disease psychosis drug Nuplazid (pimavanserin) would not be coming this year, and would need to wait until the first quarter of 2015.